<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511039</url>
  </required_header>
  <id_info>
    <org_study_id>I 650120</org_study_id>
    <nct_id>NCT04511039</nct_id>
  </id_info>
  <brief_title>Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer</brief_title>
  <official_title>A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial investigates the side effects and best dose of talazoparib when given&#xD;
      together with trifluridine/tipiracil for the treatment of patients with colorectal or&#xD;
      gastroesophageal cancer that has spread to nearby tissue or lymph nodes (locally advanced) or&#xD;
      other places in the body (metastatic). Drugs used in the chemotherapy, such as&#xD;
      trifluridine/tipiracil, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
      Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for&#xD;
      cell growth. Giving talazoparib with trifluridine/ tipiracil may inhibit certain enzymes in&#xD;
      the cells that are responsible for tumor cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the safety, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D)&#xD;
      of trifluridine and tipiracil hydrochloride (trifluridine/tipiracil [FTD/TPI]) in combination&#xD;
      with talazoparib tosylate (talazoparib) in patients with advanced colorectal (CRC) or&#xD;
      gastroesophageal (EGC) adenocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>after each cycle of treatment ( 1 cycle = 14 days)</time_frame>
    <description>All adverse events will be evaluated using Common Terminology Criteria for All Adverse Events (CTCAE) version (v.) 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose/ recommended phase II dose</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Will utilize the keyboard design - a novel model- assisted dose-finding method to find the maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration (Cmax)</measure>
    <time_frame>Day -13 post dose</time_frame>
    <description>The pharmacokinetic parameters between Trifluridine/Tipiracil and Talazoparib will be evaluated on Day -14: pre-dose, 0.5, 1, 2, 4, 6, 8 hours (hr) post-dose; day-13: 24 hr post-initial dose and day -13 pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration (Cmax)</measure>
    <time_frame>day -14 pre dose</time_frame>
    <description>The pharmacokinetic parameters between Trifluridine/Tipiracil and Talazoparib will be evaluated on Day -14: pre-dose, 0.5, 1, 2, 4, 6, 8 hours (hr) post-dose; day-13: 24 hr post-initial dose and day -13 pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration (Cmax)</measure>
    <time_frame>day -14 post dose</time_frame>
    <description>The pharmacokinetic parameters between Trifluridine/Tipiracil and Talazoparib will be evaluated on Day -14: pre-dose, 0.5, 1, 2, 4, 6, 8 hours (hr) post-dose; day-13: 24 hr post-initial dose and day -13 pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration (Cmax)</measure>
    <time_frame>day -13 pre dose</time_frame>
    <description>The pharmacokinetic parameters between Trifluridine/Tipiracil and Talazoparib will be evaluated on Day -14: pre-dose, 0.5, 1, 2, 4, 6, 8 hours (hr) post-dose; day-13: 24 hr post-initial dose and day -13 pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be summarized using frequencies and relative frequencies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEA response rate (colorectal cancer patients)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>ill be summarized using frequencies and relative frequencies. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From treatment until disease progression UP to 3 years</time_frame>
    <description>Will be summarized using standard Kaplan-Meier methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From treatment until death or up to 3 years</time_frame>
    <description>Will be summarized using standard Kaplan-Meier methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Disease Assessment (PD)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with DNA damage response</measure>
    <time_frame>Up to 28 days prior to first drug dose, on treatment and between cylce 1-day 8 and cycle 1 day 12</time_frame>
    <description>Tumor biopsies will be summarized by dose level and time-point using means and standard deviations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Advanced Malignant Solid Neoplasm</condition>
  <condition>Clinical Stage III Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Clinical Stage IV Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A</condition>
  <condition>Locally Advanced Colorectal Carcinoma</condition>
  <condition>Locally Advanced Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Metastatic Colorectal Adenocarcinoma</condition>
  <condition>Metastatic Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pathologic Stage III Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Stage III Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIIA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIIB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IIIC Colorectal Cancer AJCC v8</condition>
  <condition>Stage IV Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVC Colorectal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trifluridine/tipiracil PO BID and talazoparib tosylate PO QD on days 1-5. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine and Tipiracil Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>733030-01-8</other_name>
    <other_name>Lonsurf</other_name>
    <other_name>TAS 102,</other_name>
    <other_name>Thymidine</other_name>
    <other_name>Tipiracil Hydrochlorid Mixture with Trifluridine</other_name>
    <other_name>Trifluridine/Tipiracil</other_name>
    <other_name>Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib Tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Talzenna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed CRC or EGC adenocarcinoma that is locally&#xD;
             advanced or metastatic&#xD;
&#xD;
          -  Has received at least one prior line of therapy with progression or intolerance&#xD;
&#xD;
          -  Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1&#xD;
             criteria present&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Life expectancy &gt;= 3 months by investigator assessment&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3 without transfusion or growth factor support&#xD;
&#xD;
          -  Creatinine &lt; 1.5 upper limit of normal (ULN) or creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 2.5 x ULN or &lt; x 5&#xD;
             ULN in the presence of liver metastasis&#xD;
&#xD;
          -  Albumin &gt; 3 g/dL&#xD;
&#xD;
          -  Ability to swallow oral medications&#xD;
&#xD;
          -  Participants of child-bearing potential must agree to use adequate contraceptive&#xD;
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry. Should a woman become pregnant or suspect she is pregnant while she or her&#xD;
             partner is participating in this study, she should inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Participant must understand the investigational nature of this study and sign an&#xD;
             Independent Ethics Committee/Institutional Review Board approved written informed&#xD;
             consent form prior to receiving any study related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic antineoplastic therapy within 2 weeks prior to initiation of FTD/TPI run-in&#xD;
             phase (within the past 6 weeks if this treatment is mitomycin C or nitrosourea)&#xD;
&#xD;
          -  Radiotherapy within the past 2 weeks excluding palliative radiotherapy to painful bone&#xD;
             lesions&#xD;
&#xD;
          -  Prior treatment with PARP inhibitor or FTD/TPI&#xD;
&#xD;
          -  Any condition that in the investigator's opinion can limit absorption of FTD/TPI or&#xD;
             talazoparib from the gastrointestinal (GI) tract&#xD;
&#xD;
          -  Gastrointestinal obstruction (without diversion) or perforation within 4 weeks from&#xD;
             initiation of FTD/TPI run-in&#xD;
&#xD;
          -  Refractory ascites (requiring weekly or more frequent paracentesis or permanent&#xD;
             indwelling peritoneal catheter)&#xD;
&#xD;
          -  Untreated central nervous system (CNS) disease. Patients with leptomeningeal disease&#xD;
             are ineligible but patients with treated, stable CNS metastasis for at least 4 weeks&#xD;
             are allowed to participate&#xD;
&#xD;
          -  Significant cardiac disease defined as congestive heart failure stage III or IV (New&#xD;
             York Heart Association [NYHA]), acute coronary event, cerebrovascular event,&#xD;
             peripheral arterial embolic event, venous thromboembolic event (pulmonary embolism or&#xD;
             lower extremity deep vein thrombosis), or ventricular arrhythmia within the past 3&#xD;
             months&#xD;
&#xD;
          -  Other malignancy requiring active therapy&#xD;
&#xD;
          -  Presence of toxicities from prior therapy of grade 2 or higher&#xD;
&#xD;
          -  Active infection requiring antibiotic therapy&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) or hepatitis B infection or untreated&#xD;
             hepatitis C infection. Patients with treated hepatitis C infection and undetectable&#xD;
             viral load are allowed to participate&#xD;
&#xD;
          -  Any history of myelodysplastic syndrome, acute leukemia, or bone marrow transplant&#xD;
&#xD;
          -  Pregnant or nursing female participants&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the investigator's opinion deems the participant an unsuitable&#xD;
             candidate to receive study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos Fountzilas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christos Fountzilas, MD</last_name>
    <phone>716-845-8974</phone>
    <email>Christos.Fountzilas@roswellpark.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Fountzilas, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

